膦甲酸钠(可耐)治疗慢性乙型肝炎临床观察  

作　　者：吴群[1] 刘小兵[1] 

机构地区：[1]四川绵阳科学城医院,621900

出　　处：《中国社区医师（医学专业）》2011年第13期61-62,共2页

摘　　要：目的:观察、探讨膦甲酸钠治疗慢性乙型肝炎的疗效。方法:选择经血清定量测定乙肝HBVDNA阳性的慢性乙型肝炎88例,其中常规综合治疗组(对照组)43例,仅给予常规综合治疗,另膦甲酸钠治疗组(治疗组)45例,在综合治疗基础上加用膦甲酸钠抗病毒治疗1个月,观察两组治疗1个月后肝功能、乙肝HBV-DNA滴度下降情况。结果:肝功能改善方面治疗组明显优于对照组,治疗组乙肝HBV-DNA近期阴转率42.22%,临床有效率93.3%;对照组HBV-DNA近期阴转率11.63%,临床有效率67.4%。结论:在综合治疗基础上,膦甲酸钠具有明显的抑制HBV复制作用,改善肝功能,无明显不良反应。Objective ：To investigate the treatment efficacy of foscarnet with chronic hepatitis B. Methods：88 cases of chronic hepatitis B with serum HBV -positive HBVDNA are selected ,43 patients in the general therapy group （ control group） receive conventional combined therapy, while the foscarnet treatment group （treatment group） of 45 patients is given with foscaruet antiviral therapy in addition to regular combined therapy, after one month of treatment liver function and hepatitis B titer drop HBVDNA are observered. Results： Regarding the liver function improvement, 42.22% of recent negative rate and 93. 3% of clinical response rate in treatment group is better than 11. 63% of recent negative rate and 67.4% of clinical response rate in the control group. Conclusion： Assisted with the regular combined therapy, foscarnet shows obvious advantages in preventing HBV replication and improving liver function, no significant adverse reactions were observered.

关 键 词：慢性乙型肝炎 膦甲酸钠(可耐)临床疗效 

分 类 号：R259.126.2[医药卫生—中西医结合]